Navigation Links
Pharmaceutical Contract Manufacturing: World Market Outlook 2011-2021
Date:9/26/2011

NEW YORK, Sept. 26, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Pharmaceutical Contract Manufacturing: World Market Outlook 2011-2021

http://www.reportlinker.com/p0629356/Pharmaceutical-Contract-Manufacturing-World-Market-Outlook-2011-2021.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pharmaceutical

Report Details

How will the pharma contract manufacturing market perform from 2011? Our new report shows you potential revenues and trends to 2021, discussing opportunities and prospects. 

Discover the activities shaping the outsourcing of pharma manufacturing. Through our research and analysis we aim to save you time and help in your decisions.

How will changes in pharma affect production outsourcing and contract service providers? Which submarket and countries will give the highest revenues from 2011? Our study explains.

You can find potential revenues for pharma manufacturing services at total world, submarket and national levels to 2021. Assess prospects for contract manufacturers and their clients.

See revenue predictions and discussions for active pharmaceutical ingredient (API) and finished dosage form manufacturing. Discover opportunities in biologics and small-molecule drugs. Find data you need in our report.

Assess companies such as Catalent, Lonza, Patheon, Divis Laboratories, Royal DSM, Boehringer Ingelheim and Piramal Healthcare. Outsourcing of pharma manufacturing will become more important this decade. 

Our new report provides data, analysis and opinion to benefit your research, calculations, meetings and presentations. To get that information please respond now.

Analysis with revenues, future growth rates, market shares, opinions and discussions

In our report you find revenue forecasts, growth rates and market shares. You also receive qualitative analyses, opinions from our survey and a review of companies. Discover 85 tables and charts and two research interviews (shown in the accompanying lists).

Pharmaceutical Contract Manufacturing: World Market Outlook 2011-2021 shows you opportunities, challenges and revenue forecasts

Our report gives you the following advantages:

• Discover revenue forecasts to 2021 for the overall world market 

• Receive revenue forecasts to 2021 for submarkets, finding growth potential

• Investigate pharma contract manufacturing for a range of technologies and applications

• Assess leading companies in production outsourcing, finding activities and outlooks

• Discover revenue forecasts to 2021 for the US, Japan, Germany, France, Italy, the UK, Spain, India and China

• Assess competition and opportunities that will influence revenues

• Find out what will stimulate and restrain the industry and market from 2011

• View opinions from authorities on pharma outsourcing, seeing different perspectives.

There, you find a distinctive mix of quantitative and qualitative analysis with independent predictions. We tackle crucial questions in pharma manufacturing, helping you to stay ahead.

Order our report now to gain industry and market analysis for contract manufacturing

Our report is for everybody needing industry and market analysis for pharma contract manufacturing. Find trends and answers. Avoid missing out – please order our report now.

Visiongain is a trading partner with the US Federal Government

CCR Ref number: KD4R6 

Companies Listed

Abbott Laboratories

Aenova (formerly Dragenopharm Apotheker Püschl and Swiss Caps)

Akrimax Pharmaceuticals

AlgoNomics (now part of Lonza)

Amgen

AstraZeneca

Australian Therapeutic Goods Administration (TGA)

Avesthagen

Bayer

BIOLYPH

Biopharma Technology

Boehringer Ingelheim

Bridgepoint

Cardinal Health

Catalent

Centocor (a subsidiary of J&J)

Charles River Laboratories

Chongqing Carelife Pharmaceutical

Chongqing Daxin Pharmaceutical

CMIC CMO

CMIC CMO Korea

CMIC CMO Toyama

CMIC CMO USA

CMIC Group

Cobra Biomanufacturing (now RecipharmCobra Biologics)

Covance

Daiichi Sankyo

Department of Pharmaceuticals [India]

Divis Laboratories

Eli Lilly

European Fine Chemicals Group (EFCG)

European Medicines Agency (EMA)

Evonik Degussa

Famar

Fareva

FDA Office of Combination Products (OCP) [US]

Food and Drug Administration (FDA) [US]

Gallus BioPharmaceuticals

GlaxoSmithKline (GSK)

Haupt Pharma

Haupt Pharma Amareg

Hetero Drugs

Hollister (now Jubilant HollisterStier Contract Manufacturing and Services)

Hospira

Human Genome Sciences

International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH)

Janssen-Cilag (subsidiary of J&J)

Johnson & Johnson (J&J)

Jubilant Life Sciences (formerly Jubilant Organosys)

Kemwell

Lonza

Lupin Pharmaceuticals

Lyka Labs

Lyofal

Lyophilization Services of New England

Lyophilization Technology

Marinopoulos Group

Medicines and Healthcare Products Regulatory Agency (MHRA) [UK]

Merck & Co.

Microtest Laboratories

Millennium Pharmaceuticals

Ministry of Health, Labor and Welfare (MHLW) [Japan]

Mitsubishi Tanabe Pharma

NKT Therapeutics

Novartis

Orchid Chemicals and Pharmaceuticals

Oregon Freeze Dry

Orexigen Therapeutics

Oxford BioMedica

Pantec

Parexel

Patheon

Pfenex

Pfizer

Pharmaceuticals and Medical Devices Agency (PMDA) [Japan]

Polymed Therapeutics

PPD

PRWT Services

Quintiles

Recipharm

Recipharm Parets

Ridgemont Equity Partners

Roche

rommelag

Royal DSM

SAFC

SafeBridge Consultants

Samsung

Sanofi

Schering-Plough (now part of Merck & Co.)

SCM Pharma (formerly Specials Clinical Manufacturing)

Shandong New Time Pharmaceutical

Sinochem Group

Society of Chemical Manufacturers and Affiliates (SOCMA) [US]

Solvay Pharmaceuticals (now part of Abbott Laboratories)

Specialty European Pharma

State Food and Drug Administration (SFDA) [China]

Sun Pharmaceutical Industries

Takeda Pharmaceutical Company

Teva Pharmaceutical Industries

The Blackstone Group

The Specials Laboratory

TraceLink

US Government Accountability Office (GAO)

Vivante GMP Solutions (now part of Lonza)

Wasserburger Arzneimittelwerk (now part of Recipharm)

Wockhardt

World Health Organization (WHO)

World Trade Organization (WTO)

Wyeth (now part of Pfizer)

Zhejiang Jiuzhou Pharmaceutical

Table of Contents

1. Executive Summary

1.1 Pharmaceutical Contract Manufacturing: Market Review

1.2 Chapter Breakdown

1.3 Research and Analysis Methods

2. Introduction to Pharmaceutical Contract Manufacturing

2.1 Pharmaceutical Outsourcing

2.1.1 Contract Research Organisations (CROs)

2.1.2 Contract Manufacturing Organisations (CMOs)

2.1.2.1 Contract Development and Manufacturing Organisations (CDMOs)

2.2 Reasons for Outsourcing Manufacturing

2.2.1 Tactical Outsourcing

2.2.1.1 A Lack of Capacity

2.2.2 Strategic Outsourcing

2.2.2.1 Big Pharma Focusing on Core Competencies

2.2.3 The Rise of Generics

2.2.4 The Rise of Biotechnology

2.2.5 Virtual Companies

3. The Pharmaceutical Contract Manufacturing Market 2011-2021

3.1 The Pharmaceutical Contract Manufacturing Market in 2010

3.1.1 Recent Trends in the Contract Manufacturing Industry and Market

3.2 Pharmaceutical Contract Manufacturing Market Forecast 2011-2021

3.3 Contract API Manufacturing

3.3.1 API Manufacturing Market 2010

3.3.2 API Manufacturing Market Forecast 2011-2021

3.3.3 Highly Potent APIs (HPAPIs)

3.3.3.1 SAFC: Specialising in HPAPIs 

3.4 Contract Finished Dosage Form Manufacturing

3.4.1 Finished Dosage Form Market in 2010

3.4.2 Finished Dosage Form Market Forecast 2011-2021

3.4.3 Injectables

4. Leading Contract Manufacturing Organisations in 2011

4.1 A Highly Fragmented Market

4.2 Catalent

4.2.1 Revenues and Recent Performance Analysis

4.2.2 Expanded Oral Delivery Technologies

4.3 Lonza

4.3.1 Revenue and Recent Performance Analysis

4.3.2 Lonza Leveraging its Biologics Expertise

4.3.2.1 Teva and Lonza's Biosimilars Joint Venture

4.4 Royal DSM (DSM)

4.4.1 Revenue and Recent Performance Analysis

4.4.2 Future Outlook

4.5 Boehringer Ingelheim

4.5.1 Revenue and Recent Performance Analysis

4.5.2 Boehringer Acquires Amgen's Biopharmaceutical Facility

4.5.3 Boehringer Partners with Pfenex

4.6 Patheon

4.6.1 Revenue and Recent Performance Analysis

4.6.1.1 Patheon Forms Alliance with India's Kemwell

4.6.2 Expanded Services

4.7 Famar

4.7.1 New Facilities in Spain Expanding Famar's Reach

4.8 Fareva

4.9 Haupt Pharma

4.9.1 Haupt Pharma Increases its Capacity

4.10 Aenova

4.11 Recipharm

4.11.1 Revenue and Recent Performance Analysis

4.11.2 Recipharm's 2010 Acquisitions

4.11.3 Future Growth

4.12 Divis Laboratories

4.12.1 Revenue and Recent Performance Analysis

4.13 Jubilant Life Sciences

4.13.1 Revenue and Recent Performance Analysis

4.14 Piramal Healthcare

4.14.1 Revenue and Recent Performance Analysis

4.14.2 Piramal Seeking to Expand

4.15 Evonik Degussa

4.16 Kemwell

4.16.1 Facility and Service Expansion

5. Contract Manufacturing Industry Trends 2011-2021

5.1 The Decision to Outsource Manufacturing

5.2 Risks in Contract Manufacturing 

5.3 Technology Transfer

5.4 Globalisation

5.4.1 The Appeal of Asia

5.5 CMO Proximity

5.6 Surviving in an Increasingly Competitive Market

5.6.1 CMO Consolidation

5.6.2 Strategic Partnering

5.6.3 Buying-Out Pharma's Facilities

5.6.3.1 There Are Risks in Buying-Out Pharma's Facilities

5.6.4 The Risk of Overcapacity

5.6.5 CMO Specialisation as a Way to Compete

5.6.5.1 Lyophilisation

5.6.5.2 Highly Potent APIs and Complex Molecules

5.7 Quality by Design (QbD) and Process Analytical Technology

5.8 CMOs and Biologics

5.8.1 Biosimilars Offer New Opportunities

5.8.2 Therapeutic Peptides Remain a Strong Market Opportunity

5.9 Virtual Companies

5.10 Outsourcing to Emerging Markets

6. Regulatory Developments for Contract Manufacturing 2011-2021

6.1 Good Manufacturing Practice (GMP)

6.1.1 Harmonisation of Global Requirements

6.1.1.1 US, Australian and EU Collaboration

6.2 US Manufacturing Regulations

6.2.1 Recent and Future Developments

6.2.1.1 Foreign API Manufacture

6.3 European Manufacturing Regulations

6.3.1 The Qualified Person

6.3.2 APIs in the EU

6.3.3 Changes to EU GMP Regulations

6.4 GMP in Japan

6.5 Manufacturing Regulations in India

6.6 China: New GMP Regulations for 2011

7. Leading National Contract Manufacturing Markets 2011-2021

7.1 Breakdown of the World Pharmaceutical Market 2010

7.2 The US Market

7.3 The European Market

7.3.1 Germany and France

7.3.2 Italy

7.3.3 Spain

7.3.4 The UK

7.3.4.1 SCM Pharma: An Example of Specialisation

7.4 The Japanese Market

7.4.1 CMIC CMO: a Leading Japanese CMO

7.5 The Indian Market

7.5.1 India as an Outsourcing Destination

7.5.1.1 Indian Intellectual Property

7.6 The Chinese Market

7.6.1 China as an Outsourcing Destination

7.7 Chapter Summary

8. Opinions from Our Survey of the Industry

8.1 Alex Mello, Director of Project Management, Microtest Laboratories

8.1.1 Microtest Laboratories

8.1.2 Technological Developments to Benefit CMOs

8.1.3 Opportunities in the US Contract Manufacturing Market

8.1.4 Restraints in the US Contract Manufacturing Market

8.1.5 Clinical Trial Material Manufacture

8.1.6 CMOs Expanding Their Services

8.2 Hervé Bichon, Vice President, Pharma Sales, Fareva

8.2.1 Technological Developments to Benefit CMOs

8.2.2 Commercial Restraints and Opportunities in the European Pharmaceutical Contract Manufacturing Market

8.2.3 The Role of the Full-Service CMO

8.2.4 South America as an Opportunity

9. Conclusions

9.1 Market Growth 2011-2021

9.1.1 Demand for Contract Manufacturing Will Increase Worldwide

9.1.2 Trend in Outsourcing to Asia Will Continue

9.2 Market Consolidation

9.3 The Rise of Biologics and Biosimilars

List of Tables

Table 1.1 Currency Exchange Rates, 2010

Table 2.1 Leading Biological Drugs by Revenue, 2010

Table 3.1 Pharmaceutical Contract Manufacturing Market, 2010

Table 3.2 Pharmaceutical Outsourcing Market, 2010

Table 3.3 Leading Developed Market Companies Revenue Growth, 2009-2010

Table 3.4 Pharmaceutical Contract Manufacturing: Market Forecasts for Total Market, APIs and Finished Dosage Form, 2010-2021

Table 3.5 Pharmaceutical Contract Manufacturing: Market Drivers and Restraints, 2011-2021

Table 3.6 API Contract Manufacturing: Market Drivers and Restraints, 2011-2021

Table 3.7 Finished Dosage Form Contract Manufacturing: Market Drivers and Restraints, 2011-2021

Table 4.1 Catalent Revenue by Sector, 2010

Table 4.2 Catalent Contract Manufacturing Revenue, 2010

Table 4.3 Catalent Contract Manufacturing Revenue, Q1-Q3 2011

Table 4.4 Lonza Revenue, 2010

Table 4.5 DSM Pharmaceutical Products Revenue, 2009-2010

Table 4.6 Boehringer Ingelheim Revenue, 2009-2010

Table 4.7 Patheon Revenue by Sector, 2009-2010

Table 4.8 Patheon Contract Manufacturing Revenue by Region, 2009-2010

Table 4.9 Recipharm Revenue by Sector and Region, 2010

Table 4.10 Divis Laboratories Revenue, 2010-2011

Table 4.11 Divis Laboratories Revenue by Region, 2010

Table 4.12 Jubilant Life Sciences Revenue by Sector, 2010-2011

Table 4.13 Jubilant Life Sciences Pharmaceutical and Life Sciences Revenue, 2010

Table 4.14 Jubilant Life Sciences CRAMS Revenue, 2010

Table 5.1 SWOT Analysis for the Pharmaceutical Contract Manufacturing Market, 2011-2021

Table 5.2 BRIC Sites for Leading CMOs and CROs, 2011

Table 5.3 BRIC Sites for Leading CMOs and CROs by Country, 2011

Table 5.4 Selected Manufacturing Site Buyouts, 2009-2011

Table 5.5 Selected CMOs Specialising in Lyophilisation, 2011

Table 5.6 Lyophilisation Services: Market Forecast, 2010-2021

Table 5.7 Biological Drugs: Market Forecast, 2010-2021

Table 5.8 India and China: Contract Manufacturing SWOT Chart, 2011-2021

Table 5.9 Top US DMF Holders in India and China, 2007-2008

Table 6.1 FDA Foreign Manufacturing Site Inspections, 2007-2009 

Table 7.1 Pharmaceutical Contract Manufacturing Market by Region, 2010

Table 7.2 Pharmaceutical Contract Manufacturing: Market Forecasts by Region, 2010-2021

Table 7.3 European Pharmaceutical Contract Manufacturing Market, 2010

Table 7.4 EU Membership Status of CEE Countries, 2011

Table 7.5 European Pharmaceutical Contract Manufacturing: Market Forecasts for Leading Countries, 2010-2021

Table 7.6 CMIC CMO Revenue, 2009-2011

Table 9.1 Pharmaceutical Contract Manufacturing: Market Forecasts, 2010, 2016 and 2021

Table 9.2 Pharmaceutical Contract Manufacturing: Market Forecasts by Country, 2010, 2016 and 2021

List of Figures

Figure 2.1 Outsourcing the Pharmaceutical Product Lifecycle

Figure 2.2 Expanding Roles of CROs and CMOs, 2011

Figure 2.3 Leading Biological Drugs by Revenue, 2010

Figure 3.1 Pharmaceutical Contract Manufacturing World Market, 2010

Figure 3.2 Pharmaceutical Outsourcing Market, 2010

Figure 3.3 Leading Developed-Market Companies: Revenue Growth, 2009-2010

Figure 3.4 Pharmaceutical Contract Manufacturing: Market Forecasts, 2010-2021

Figure 3.5 API Contract Manufacturing: Market Forecast, 2010-2021

Figure 3.6 Finished Dosage Form Contract Manufacturing: Market Forecast, 2010-2021

Figure 4.1 Catalent Revenue by Sector, 2010

Figure 4.2 Catalent Contract Manufacturing Revenue, 2010

Figure 4.3 Catalent Contract Manufacturing Revenue, Q1-Q3 2011

Figure 4.4 Lonza Revenue, 2010

Figure 4.5 DSM Pharmaceutical Products Revenue, 2009-2010

Figure 4.6 Boehringer Ingelheim Revenue, 2009-2010

Figure 4.7 Patheon Revenue by Sector, 2009-2010

Figure 4.8 Patheon Contract Manufacturing Revenue by Region, 2010

Figure 4.9 Recipharm Revenue by Sector and Region, 2010

Figure 4.10 Divis Laboratories Revenue, 2010-2011

Figure 4.11 Divis Laboratories Revenue by Region, 2010

Figure 4.12 Jubilant Life Sciences CRAMS Revenue, 2010

Figure 5.1 Cost-Benefit Analysis for Strategic Outsourcing

Figure 5.2 BRIC Sites for Leading CMOs and CROs by Country, 2011

Figure 5.3 Lyophilisation Services: Market Forecast, 2010-2021

Figure 5.4 Biological Drugs: Market Forecast, 2010-2021

Figure 6.1 ICH Manufacturing Guidelines: Developed Market Adoption, 2000-2010 

Figure 6.2 FDA Foreign Manufacturing Site Inspections, 2009

Figure 7.1 Pharmaceutical Contract Manufacturing Market by Region, 2010 

Figure 7.2 US Contract Manufacturing: Market Forecast, 2010-2021

Figure 7.3 European Pharmaceutical Contract Manufacturing Market, 2010

Figure 7.4 European Pharmaceutical Contract Manufacturing: Market Forecast, 2010-2021

Figure 7.5 French and German Pharmaceutical Contract Manufacturing: Market Forecasts, 2010-2021

Figure 7.6 Italian Pharmaceutical Contract Manufacturing: Market Forecast, 2010-2021

Figure 7.7 Spanish Pharmaceutical Contract Manufacturing: Market Forecast, 2010-2021

Figure 7.8 UK Pharmaceutical Contract Manufacturing: Market Forecast, 2010-2021

Figure 7.9 Japanese Pharmaceutical Contract Manufacturing: Market Forecast, 2010-2021

Figure 7.10 CMIC CMO Revenue, 2009-2011

Figure 7.11 Indian Pharmaceutical Contract Manufacturing: Market Forecast, 2010-2021

Figure 7.12 Indian Intellectual Property Law 1970-2011

Figure 7.13 Chinese Pharmaceutical Contract Manufacturing: Market Forecast, 2010-2021

Figure 7.14 Pharmaceutical Contract Manufacturing Market by Region, 2016

Figure 7.15 Pharmaceutical Contract Manufacturing Market by Region, 2021

Figure 9.1 Pharmaceutical Contract Manufacturing: Market Forecasts, 2010, 2016 and 2021

Figure 9.2 Pharmaceutical Contract Manufacturing: Market Forecasts by Region, 2010, 2016 and 2021

To order this report:

Pharmaceutical Industry: Pharmaceutical Contract Manufacturing: World Market Outlook 2011-2021

Pharmaceutical Business News

More  Industry Analysis and Insights

Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved


Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... DUBLIN , June 24, 2016 ... and Markets has announced the addition of the ... their offering. ... products and provides an updated review, including its applications ... covering the total market, which includes three main industries: ...
(Date:6/24/2016)... 2016 Dehaier Medical Systems Ltd. (NASDAQ: ... markets and sells medical devices and wearable sleep respiratory ... strategic cooperation agreement with Hongyuan Supply Chain Management Co., ... June 20, 2016, to develop Dehaier,s new Internet medical ... Dehaier will leverage Hongyuan Supply Chain,s sales platform to ...
(Date:6/24/2016)... June 24, 2016 According to ... Type (Standard Pen Needles, Safety Pen Needles), Needle Length ... Growth Hormone), Mode of Purchase (Retail, Non-Retail) - Trends ... report studies the market for the forecast period of ... USD 2.81 Billion by 2021 from USD 1.65 Billion ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is helping ... fitness app. The fitness app plans to fix the two major problems leading the fitness ... size fits all type program , They don’t eliminate all the reasons people ...
(Date:6/25/2016)... ... ... temporary closing of Bruton Memorial Library on June 21 due to a possible lice infestation, ... aspect of head lice: the parasite’s ability to live away from a human host, and ... necessary one in the event that lice have simply gotten out of control. , As ...
(Date:6/25/2016)... ... 25, 2016 , ... Dr. Calvin Johnson has dedicated his ... implemented orthobiologic procedures as a method for treating his patients. The procedure is ... to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to help ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may suffer ... unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To avoid ... healthy coping following a traumatic event. , Trauma sufferers tend to feel a range ...
(Date:6/24/2016)... MIAMI, Fla. (PRWEB) , ... June 24, 2016 , ... ... Florida Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this ... of Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this ...
Breaking Medicine News(10 mins):